Effects of one-year treatment with canagliflozin or sitagliptin on glycaemic control and beta cell function measures in subjects with type 2 diabetes on metformin plus sulfonylurea

被引：0
|
作者：
Schernthaner, G. [1 ]
Ferrannini, E. [2 ]
Mari, A. [3 ]
Tong, C. [4 ]
Kawaguchi, M. [4 ]
Meininger, G. [4 ]
Polidori, D. [4 ]
机构：
[1] Rudolfstiftung Hosp Vienna, Vienna, Austria
[2] Univ Pisa, Sch Med, I-56100 Pisa, Italy
[3] CNR, Inst Biomed Engn, Padua, Italy
[4] Janssen R&D LLC, Raritan, NJ USA
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
993
引用
收藏
页码：S398 / S399
页数：2
相关论文
共 50 条
  • [31] Effects of pioglitazone and metformin on β-cell function in nondiabetic subjects at high risk for type 2 diabetes
    Rasouli, Neda
    Kern, Philip A.
    Reece, E. Albert
    Elbein, Steven C.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (01): : E359 - E365
  • [32] Initial treatment with metformin plus colesevelam provides greater glycaemic control than metformin alone in Hispanic patients with type 2 diabetes mellitus
    Hernandez-Triana, E.
    Garvey, W. T.
    Goldberg, R. B.
    Handelsman, Y.
    Fonseca, V. A.
    Jones, M. R.
    Abby, S. L.
    Markiewicz, M.
    Jin, X.
    Misir, S.
    Nagendran, S.
    Rosenstock, J.
    DIABETOLOGIA, 2010, 53
  • [33] Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves indices of beta cell function in patients with type 2 diabetes on metformin plus sulphonylurea
    Polidori, D.
    Vercruysse, F.
    Ferrannini, E.
    DIABETOLOGIA, 2012, 55 : S313 - S313
  • [34] Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes
    Poucher, S. M.
    Cheetham, S.
    Francis, J.
    Zinker, B.
    Kirby, M.
    Vickers, S. P.
    DIABETES OBESITY & METABOLISM, 2012, 14 (10): : 918 - 926
  • [35] Basic Characteristics, Antidiabetic Treatment and Glycaemic Status of Type 2 Diabetes Patients in China: One-Year Results from IDMPS
    Jia, Weiping
    Ji, Linong
    Weng, Jianping
    DIABETES, 2009, 58 : A515 - A516
  • [36] Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes inadequately controlled with metformin: the VERTIS FACTORIAL trial
    Pratley, R.
    Eldor, R.
    Golm, G.
    Huyck, S.
    Qiu, Y.
    Sunga, S.
    Johnson, J.
    Terra, S.
    Mancuso, J.
    Engel, S. S.
    Lauring, B.
    DIABETOLOGIA, 2016, 59 : S347 - S347
  • [37] Beta cell function improvements in subjects with type 2 diabetes 1 year ater biliopancreatic diversion
    Vasques, A. C. J.
    Pareja, J. C.
    Oliveira, M. S.
    Novaes, F. S.
    Lima, M. M. O.
    Chaim, E. A.
    Piccinini, F.
    Man, C. Dalla
    Cobelli, C.
    Geloneze, B.
    DIABETOLOGIA, 2014, 57 : S59 - S59
  • [38] Variation in daytime glycaemic control, pancreatic beta-cell function and insulin sensitivity in type 2 diabetic subjects
    Peter, R
    Dunseath, G
    Luzio, S
    Mustafa, N
    Pauvaday, V
    Owens, DR
    DIABETES, 2005, 54 : A419 - A419
  • [39] The effects of once-weekly semaglutide on beta cell function in subjects with type 2 diabetes
    Kapitza, C.
    Dahl, K.
    Jacobsen, J. Bonde
    Axelsen, M. Buhl
    Flint, A.
    DIABETOLOGIA, 2016, 59 : S358 - S359
  • [40] Canagliflozin (CANA) Improves Risk Factors of Metabolic Syndrome (MetS) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) and MetS on Background Metformin (MET) plus Sulfonylurea (SU)
    Davies, Michael J.
    Merton, Katherine
    Vijapurkar, Ujjwala
    Balis, Dainius
    Desai, Mehul
    DIABETES, 2016, 65 : A286 - A286
12345